ValuEngine cut shares of VERONA PHARMA P/S (NASDAQ:VRNA) from a buy rating to a hold rating in a research note released on Wednesday morning.

Several other research firms also recently weighed in on VRNA. Zacks Investment Research downgraded shares of VERONA PHARMA P/S from a strong-buy rating to a hold rating in a research report on Saturday, August 25th. Wedbush set a $56.00 price target on shares of VERONA PHARMA P/S and gave the stock a buy rating in a research report on Tuesday, August 7th. Finally, Jefferies Financial Group reiterated a buy rating and issued a $26.00 price target on shares of VERONA PHARMA P/S in a research report on Friday, August 10th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $31.33.

VRNA opened at $11.00 on Wednesday. VERONA PHARMA P/S has a 1-year low of $10.19 and a 1-year high of $25.55.

VERONA PHARMA P/S (NASDAQ:VRNA) last released its quarterly earnings results on Tuesday, November 6th. The company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.26. On average, research analysts forecast that VERONA PHARMA P/S will post -2.12 EPS for the current year.

A hedge fund recently bought a new stake in VERONA PHARMA P/S stock. Foresite Capital Management IV LLC acquired a new position in VERONA PHARMA P/S (NASDAQ:VRNA) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,302 shares of the company’s stock, valued at approximately $104,000. VERONA PHARMA P/S makes up approximately 0.0% of Foresite Capital Management IV LLC’s investment portfolio, making the stock its 21st largest holding. Foresite Capital Management IV LLC owned about 0.06% of VERONA PHARMA P/S as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 56.23% of the company’s stock.

About VERONA PHARMA P/S

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

Further Reading: What is an SEC Filing?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for VERONA PHARMA P/S (NASDAQ:VRNA)

Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.